226 related articles for article (PubMed ID: 25640825)
1. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
Wang H; Wu H; Bao S; Xiang X; Zhao G; Liu K; Li F; Xu Y; An B; Zhou H; Lu J; Xie Q
Infect Genet Evol; 2015 Apr; 31():161-8. PubMed ID: 25640825
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
3. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
4. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
5. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study.
Lee IC; Huang YH; Su CW; Wang YJ; Huo TI; Lee KC; Lin HC
PLoS One; 2013; 8(10):e76798. PubMed ID: 24124595
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2015 Mar; 22(3):318-27. PubMed ID: 25060765
[TBL] [Abstract][Full Text] [Related]
7. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1257-1264. PubMed ID: 31030503
[TBL] [Abstract][Full Text] [Related]
9. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
[TBL] [Abstract][Full Text] [Related]
10. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
12. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
13.
Xie DY; Wang SM; Yang JM; Wang LH; Chen HY; Huai C; Shang J; Mao Q; Lei CL; Luo GH; Qian J; Lu DR
World J Gastroenterol; 2016 Nov; 22(44):9813-9821. PubMed ID: 27956805
[TBL] [Abstract][Full Text] [Related]
14. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.
Wu H; Zhao G; Qian F; Liu K; Xie J; Zhou H; Xu J; Xu Y; Han Y; Xie Q; Wang H
Liver Int; 2015 Feb; 35(2):473-81. PubMed ID: 24517415
[TBL] [Abstract][Full Text] [Related]
15. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
18. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
19. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
20. Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon.
Wang X; Xu ZQ; Fu JJ; Cheng LW; Li Y; Li L; Pan XC
Medicine (Baltimore); 2018 Jun; 97(23):e10891. PubMed ID: 29879024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
